#SFHS2611537VPrices Set for VGENFLI Pharmaceutical Products
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This notice sets the official pre-tax and tax-included prices for two VGENFLI 40 mg/ml aflibercept injectable products marketed by Fresenius Kabi France: one vial presentation and one pre-filled syringe presentation. Both are priced at €212.05 before tax and €248.21 including tax. The change affects Fresenius Kabi France, pharmacies, healthcare purchasers, reimbursement administrators, and healthcare providers using or supplying these products. The prices apply from the fourth day after publication in the French Official Journal.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Sets the official pre-tax price of each listed VGENFLI product at €212.05
- Sets the official tax-included price of each listed VGENFLI product at €248.21
- Applies the new prices from the fourth day after publication in the French Official Journal
Obligations
What this law requires
Apply the official price of €212.05 before tax and €248.21 including tax for VGENFLI 40 mg/ml aflibercept solution injectable in vial presentation, CIP 34009 303 364 6 5.
Apply the official price of €212.05 before tax and €248.21 including tax for VGENFLI 40 mg/ml aflibercept solution injectable in pre-filled syringe presentation, CIP 34009 303 364 5 8.